BioHarvest Sciences Inc. (BHST) Earnings Call Transcripts

BioHarvest Sciences Inc.'s Latest Earnings Call - Q1 FY2026

In the first quarter of 2026, BioHarvest Sciences Inc. (BHST:US) reported revenues of $8.5 million, an 8% increase from $7.9 million in the prior year, while net losses widened slightly to $2.6 million or $0.11 per share. The company maintained its guidance for total CDMO revenue between $12 million and $14 million for the year, alongside a D2C revenue forecast of $38 million to $42 million. Management emphasized a strategic shift towards optimizing its dual business model, which could enhance operational performance and shareholder value moving forward.

Reported metrics

Guidance from management

Management maintained its revenue guidance for the CDMO business at $12 million to $14 million and for the D2C business at $38 million to $42 million for the fiscal year 2026.

What management said

The answer is no. No. That's been -- that's -- No, that's a very modest increase as a result of hiring. And in fact, I did have last year -- it's actually a replacement of someone that I had last year. So it's actually not even a new additional person in -- overall in the budget. No. And for purpose of what we're trying to do this year, there would be no increase in the marketing costs for the CDMO.

I would just add that it's a very important asset that the CDMO has because now when we engage with the customers in this area who are starting a project with us, they have ability to be able to develop a unique molecule at a cellular level. And with that, they also have the potential of developing one of these extracellular vesicles in addition. So it's like a one plus one, which makes our CDMO proposition to custom...

What analysts pressed on

Analysts expressed concerns regarding the slow growth in the D2C segment and the impact of the reset strategy on future revenues. There were questions about the timeline for new product launches and how effectively the new marketing strategies would translate into sales growth.

Main topics on the call

• Revenue Growth — BioHarvest reported a revenue increase of 8% year-over-year, reaching $8.5 million compared to $7.9 million in Q1 2025. Management stated, 'We believe that the unique scalable capability of our technology significantly e...
• CDMO Business Development — The CDMO division signed a $1.2 million Stage 2 contract, marking a significant milestone in its development program. Management noted, 'This phase of the process is considered Stage 1, where a stable cell bank of a uniq...
• D2C Business Strategy — Management acknowledged a reset in the D2C strategy, which impacted Q1 revenue but is expected to yield better results in Q2 and beyond. CEO Zaki Rakib stated, 'Q1 was a reset quarter for VINIA,' indicating a focus on op...
• Marketing Optimization — The company is refining its marketing strategy to improve customer acquisition costs and lifetime value ratios. Ilan Sobel mentioned, 'We expect Q2 results to improve versus Q1,' highlighting a shift towards digital chan...

Read the full BioHarvest Sciences Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 7 BioHarvest Sciences Inc. earnings call transcripts on record, spanning March 31, 2025 to May 14, 2026. Based on this history, BioHarvest Sciences Inc. reports quarterly. The most recent call on file is dated May 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BHST

Exchange

NasdaqGM

Country

US

Sector

Consumer Staples

Industry

Personal Care Products

Calls on record

7

First call

March 31, 2025

Most recent

May 14, 2026

Reporting cadence

quarterly